Population pharmacokinetic analysis of daikenchuto, a traditional Japanese medicine (kampo) in Japanese and US health volunteers

Drug Metabolism and Disposition

Volumn 41, Issue 6, 2013, Pages 1256-1263

  Munekage, Masaya ^a   Ichikawa, Kengo ^a   Kitagawa, Hiroyuki ^a   Ishihara, Kazuhisa ^b   Uehara, Hideaki ^b   Watanabe, Junko ^b   Kono, Toru ^c   Hanazaki, Kazuhiro ^a  

^a KOCHI MEDICAL SCHOOL   (Japan)

^b TSUMURA AND CO   (Japan)

^c Sapporo Higashi Tokushukai Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

10 SHOGAOL; 6 SHOGAOL; DAIKENCHUTO; GINSENOSIDE RB 1; HERBACEOUS AGENT; HYDROXY ALPHA SANSHOOL; HYDROXYL BETA SANSHOOL; KAMPO; PLANT MEDICINAL PRODUCT; UNCLASSIFIED DRUG;

ADULT; AGE; AREA UNDER THE CURVE; ARTICLE; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISTRIBUTION; ETHNIC DIFFERENCE; FEMALE; HUMAN; HUMAN EXPERIMENT; JAPAN; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; TRADITIONAL MEDICINE; UNITED STATES;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CROSS-OVER STUDIES; FEMALE; HUMANS; JAPAN; MALE; MEDICINE, TRADITIONAL; MIDDLE AGED; PLANT EXTRACTS; POPULATION SURVEILLANCE; UNITED STATES;

EID: 84878218922     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.050112     Document Type: Article

References (20)

1. Beal SL (2001) Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn 28:481-504.
2. Byon W, Fletcher CV, and Brundage RC (2008) Impact of censoring data below an arbitrary quantification limit on structural model misspecification. J Pharmacokinet Pharmacodyn 35:101-116.
3. Ette EI (1997) Stability and performance of a population pharmacokinetic model. J Clin Pharmacol 37:486-495.
4. Hing JP, Woolfrey SG, Greenslade D, and Wright PM (2001) Analysis of toxicokinetic data using NONMEM: impact of quantification limit and replacement strategies for censored data. J Pharmacokinet Pharmacodyn 28:465-479.
5. Itoh T, Yamakawa J, Mai M, Yamaguchi N, and Kanda T (2002) The effect of the herbal medicine dai-kenchu-to on post-operative ileus. J Int Med Res 30:428-432.
6. Iwabu J, Watanabe J, Hirakura K, Ozaki Y, and Hanazaki K (2010) Profiling of the compounds absorbed in human plasma and urine after oral administration of a traditional Japanese (kampo) medicine, daikenchuto. Drug Metab Dispos 38:2040-2048.
7. Kono T, Kaneko A, Hira Y, Suzuki T, Chisato N, Ohtake N, Miura N, and Watanabe T (2010) Anti-colitis and -adhesion effects of daikenchuto via endogenous adrenomedullin enhancement in Crohn's disease mouse model. J Crohn's Colitis 4:161-170.
8. Kono T, Kanematsu T, and Kitajima M (2009) Exodus of Kampo, traditional Japanese medicine, from the complementary and alternative medicines: is it time yet? Surgery 146:837-840.
9. Kono T, Koseki T, Chiba S, Ebisawa Y, Chisato N, Iwamoto J, and Kasai S (2008) Colonic vascular conductance increased by Daikenchuto via calcitonin gene-related peptide and receptor-activity modifying protein 1. J Surg Res 150:78-84.
10. Kono T, Omiya Y, Hira Y, Kaneko A, Chiba S, Suzuki T, Noguchi M, and Watanabe T (2011) Daikenchuto (TU-100) ameliorates colon microvascular dysfunction via endogenous adrenomedullin in Crohn's disease rat model. J Gastroenterol 46:1187-1196.
11. Manabe N, Camilleri M, Rao A, Wong BS, Burton D, Busciglio I, Zinsmeister AR, and Haruma K (2010) Effect of daikenchuto (TU-100) on gastrointestinal and colonic transit in humans. Am J Physiol Gastrointest Liver Physiol 298:G970-G975.
12. Munekage M, Kitagawa H, Ichikawa K, Watanabe J, Aoki K, Kono T, and Hanazaki K (2011) Pharmacokinetics of daikenchuto, a traditional Japanese medicine (kampo) after single oral administration to healthy Japanese volunteers. Drug Metab Dispos 39:1784-1788.
13. Murata P, Kase Y, Ishige A, Sasaki H, Kurosawa S, and Nakamura T (2002) The herbal medicine Dai-kenchu-to and one of its active components [6]-shogaol increase intestinal blood flow in rats. Life Sci 70:2061-2070.
14. Ohya T, Usui Y, Arii S, Iwai T, and Susumu T (2003) Effect of dai-kenchu-to on obstructive bowel disease in children. Am J Chin Med 31:129-135.
15. Post TM, Freijer JI, Ploeger BA, and Danhof M (2008) Extensions to the visual predictive check to facilitate model performance evaluation. J Pharmacokinet Pharmacodyn 35:185-202.
16. Tokita Y, Yuzurihara M, Sakaguchi M, Satoh K, and Kase Y (2007) The pharmacological effects of Daikenchuto, a traditional herbal medicine, on delayed gastrointestinal transit in rat postoperative ileus. J Pharmacol Sci 104:303-310.
17. Tokita Y, Yamamoto M, Satoh K, Nishiyama M, Iizuka S, Imamura S, and Kase Y (2011) Possible involvement of the transient receptor potential vanilloid type 1 channel in postoperative adhesive obstruction and its prevention by a kampo (traditional Japanese) medicine, daikenchuto. J Pharmacol Sci 115:75-83.
18. Wade JR, Kelman AW, Howie CA, and Whiting B (1993) Effect of misspecification of the absorption process on subsequent parameter estimation in population analysis. J Pharmacokinet Biopharm 21:209-222.
19. Wählby U, Jonsson EN, and Karlsson MO (2001) Assessment of actual significance levels for covariate effects in NONMEM. J Pharmacokinet Pharmacodyn 28:231-252.
20. Williams PJ and Ette EI (2000) The role of population pharmacokinetics in drug development in light of the Food and Drug Administration's 'Guidance for Industry: population pharmacokinetics'. Clin Pharmacokinet 39:385-395.